Welcome to our dedicated page for VERADERMICS SEC filings (Ticker: MANE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERADERMICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERADERMICS's regulatory disclosures and financial reporting.
Veradermics, Inc. director Jane M. Grant-Kels reported acquiring equity through an option grant and a preferred stock conversion. On February 3, 2026, she received a stock option for 51,525 shares of common stock at an exercise price of $17 per share, which will be fully vested and exercisable on February 3, 2027.
On February 5, 2026, 2,455 shares of Series A Convertible Preferred Stock automatically converted into 2,455 shares of common stock on a 10.067-for-1 basis, without additional payment, immediately before the closing of Veradermics’ initial public offering, leaving her with 2,455 common shares held directly.
Veradermics, Inc. reported that director David Matthew Friedman was granted a stock option covering 43,000 shares of common stock at an exercise price of $17 per share on February 3, 2026. The option is scheduled to become fully vested and exercisable on February 3, 2027.
According to the disclosure, Friedman, an employee of Suvretta Capital Management, LLC, is holding this award for the benefit of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. He disclaims beneficial ownership of the option, while the Funds and Suvretta Capital may be deemed to have an indirect pecuniary interest through rights to receive director compensation linked to his board service.
Veradermics, Inc. director Vladimir Coric reported multiple equity-acquiring transactions in connection with the company’s initial public offering. On February 5, 2026, Series A, B, and C convertible preferred shares automatically converted into common stock on a 10.067-for-1 basis immediately before the IPO closing.
These conversions resulted in common stock holdings shown at 33,706 shares from Series A, 148,794 from Series B, and additional common shares from Series C, split between direct ownership and entities referenced in the footnotes. Through the Vladimir Coric Family Trust 2013 and the Vladimir Coric Marital Trust 2013, indirect positions increased via these conversions.
On February 5, 2026, the trusts also executed an open-market purchase of 58,823 shares of common stock at $17 per share, bringing indicated indirect common stock holdings to 319,398 shares. Separately, on February 3, 2026, Coric received a stock option grant covering 51,525 shares at a $17 exercise price, which becomes fully vested and exercisable on February 3, 2027.
Veradermics, Inc. director John W. Childs reported multiple equity transactions tied to the company’s initial public offering. On February 5, 2026, entities associated with him converted Series A, B and C convertible preferred stock into Veradermics common shares on a 10.067-for-1 basis, resulting in 480,269, 906,862 and 520,758 common shares, respectively, all held indirectly through J.W. Childs Associates (FL), L.P. The same day, that entity also made an indirect open-market purchase of 294,117 common shares at $17 per share, bringing total indirect common stock holdings to 2,202,006 shares. Separately, on February 3, 2026, Childs received a direct stock option grant for 51,525 shares at a $17 exercise price, which becomes fully vested and exercisable on February 3, 2027.
Veradermics, Inc. reported insider activity by affiliated 10% owners on February 5, 2026. Investment funds Longitude Venture Partners V, L.P. and Longitude 103.8 East, L.P., through their general partner entities, converted existing Series B and Series C Convertible Preferred Stock into common stock in connection with Veradermics’ initial public offering, at a 10.067-for-1 conversion ratio without additional consideration.
The same affiliated entities also made indirect open-market or private purchases of Veradermics common stock at $17 per share, acquiring 192,647 shares in one account and 882,353 shares in another. Following these transactions, they reported multi-million-share indirect common stock holdings, while their managing entities and individuals disclaim beneficial ownership beyond their pecuniary interests.
Veradermics, Inc. director and 10% owner Patrick G. Enright reported indirect conversions and purchases of common stock. On February 5, 2026, Series B and Series C Convertible Preferred Stock automatically converted into 1,236,631 and 1,171,121 shares of common stock, respectively, on a 10.067-for-1 basis immediately before the closing of the company’s initial public offering, with no additional consideration.
Entities affiliated with Enright then bought 192,647 and 882,353 common shares at $17 per share, held through Longitude Venture Partners V, L.P. and Longitude 103.8 East, L.P., where voting and investment power is shared and beneficial ownership is disclaimed beyond pecuniary interests. On February 3, 2026, Enright also received a direct stock option for 45,131 shares at a $17 exercise price, vesting in full on February 3, 2027.
Veradermics, Inc. reported that its General Counsel, Michael V. Greco, received a grant of stock options on February 3, 2026. The award covers 144,401 stock options with an exercise price of $17 per share, held as direct beneficial ownership.
According to the vesting terms, 25% of the options vest on February 3, 2027, the first anniversary of the vesting commencement date. The remaining options vest in equal monthly installments over the following 36 months, contingent on continued service with the company.
Veradermics, Inc. reported that officer Mark Neumann, its Chief Commercial Officer and Strategy Officer, received a grant of stock options on February 3, 2026. The award covers 102,885 stock options with an exercise price of $17 per share.
According to the vesting terms, 25% of the underlying common shares vest on February 3, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, subject to continued service. After this grant, Neumann directly holds 102,885 derivative securities.
Carrano Dominic Gabriel reported acquisition or exercise transactions in a Form 4 filing for MANE. The filing lists transactions totaling 148,011 shares. Following the reported transactions, holdings were 148,011 shares.
Veradermics, Inc. Chief Technical Officer Timothy August Durso reported stock-based transactions and updated his holdings. On February 3, 2026, he received a stock option grant for 213,352 shares of common stock at an exercise price of $17 per share. The option vests 25% on February 3, 2027, with the remaining shares vesting in equal monthly installments over 36 months, subject to continued service.
On February 5, 2026, 1,473 shares of Series A Convertible Preferred Stock automatically converted to 1,473 shares of common stock on a 10.067-for-1 basis without additional payment, immediately before the company’s initial public offering. After these transactions, Durso directly held 118,190 common shares and had an option over 213,352 shares, and 116,717 common shares were held indirectly by the Durso Family Trust. The trust is for the benefit of his children, is administered by his spouse as trustee, and Durso disclaims beneficial ownership of those trust-held shares.